OBJECTIVES: The number of HIV-infected patients receiving orthotopic liver transplantation (OLTX) is increasing. One major challenge is the severe drug-drug interactions between immunosuppressive drugs such as tacrolimus and ritonavir-boosted HIV-1 protease inhibitors (PIs). The introduction of raltegravir, which is not metabolized by the cytochrome system, may allow concomitant treatment without dose adaptation. PATIENTS AND METHODS: We conducted a retrospective analysis of HIV-1-infected patients receiving tacrolimus concomitantly with different HIV therapies, including 12 h pharmacokinetic assessment of drug levels. RESULTS: Three OLTX patients received a ritonavir-boosted PI therapy when tacrolimus was added at very low doses of 0.06, 0.03 and 0.08 mg daily. Median tacrolimus blood levels were 6.6, 3.0 and 7.9 ng/mL over a follow-up period of 8, 22 and 33 months, respectively. In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily. No tacrolimus dose adjustment was necessary and drug levels remained unchanged. CONCLUSIONS: Decreasing the dose of tacrolimus to 0.03-0.08 mg daily in patients with concomitant boosted PI therapy resulted in stable tacrolimus blood levels without alteration of PI drug levels. Concomitant use of raltegravir and tacrolimus revealed no clinically relevant drug interaction.
OBJECTIVES: The number of HIV-infectedpatients receiving orthotopic liver transplantation (OLTX) is increasing. One major challenge is the severe drug-drug interactions between immunosuppressive drugs such as tacrolimus and ritonavir-boosted HIV-1 protease inhibitors (PIs). The introduction of raltegravir, which is not metabolized by the cytochrome system, may allow concomitant treatment without dose adaptation. PATIENTS AND METHODS: We conducted a retrospective analysis of HIV-1-infectedpatients receiving tacrolimus concomitantly with different HIV therapies, including 12 h pharmacokinetic assessment of drug levels. RESULTS: Three OLTX patients received a ritonavir-boosted PI therapy when tacrolimus was added at very low doses of 0.06, 0.03 and 0.08 mg daily. Median tacrolimus blood levels were 6.6, 3.0 and 7.9 ng/mL over a follow-up period of 8, 22 and 33 months, respectively. In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily. No tacrolimus dose adjustment was necessary and drug levels remained unchanged. CONCLUSIONS: Decreasing the dose of tacrolimus to 0.03-0.08 mg daily in patients with concomitant boosted PI therapy resulted in stable tacrolimus blood levels without alteration of PI drug levels. Concomitant use of raltegravir and tacrolimus revealed no clinically relevant drug interaction.
Authors: M Winkler; R Pichlmayr; P Neuhaus; P McMaster; R Calne; G Otto; R Williams; H Bismuth; C Groth Journal: Transpl Int Date: 1994 Impact factor: 3.782
Authors: M Alessiani; U Cillo; J J Fung; W Irish; K Abu-Elmagd; A Jain; S Takaya; D Van Thiel; T E Starzl Journal: Transplant Proc Date: 1993-02 Impact factor: 1.066
Authors: Ashokkumar B Jain; Raman Venkataramanan; Bijan Eghtesad; Amadeo Marcos; Margaret Ragni; Ron Shapiro; Ann B Rafail; John J Fung Journal: Liver Transpl Date: 2003-09 Impact factor: 5.799
Authors: Lynda A Frassetto; Clara C Tan-Tam; Burc Barin; Matt Browne; Alan R Wolfe; Peter G Stock; Michelle Roland; Leslie Z Benet Journal: Transplantation Date: 2014-03-27 Impact factor: 4.939
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079